NCT03832179

Steroid vs. Anti-vascular Endothelial Growth Factor for Diabetic Macular Edema Prior to Phacoemulsification

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 16 (actual)
• Sponsor: Bay Area Retina Associates · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Accepted

Summary

The primary objective of this study is to compare the efficacy of antecedent intravitreal anti-vascular endothelial growth factor therapy vs. Ozurdex in reducing post-cataract surgery related macular edema in patients with pre-existing diabetic macular edema.

Detailed description

In patients with pre-existing diabetic macular edema, anti-vascular endothelial growth factor therapy (Bevacizumab, ranibizumab, or aflibercept) will be compared to Ozurdex therapy administered 1 week prior to phacoemulsification cataract extraction. Spectral domain optical coherence tomography and visual acuity will be acquired at 1 week, 1 month, 2 months, and 3 months following cataract surgery.

Conditions

• Diabetic Macular Edema
• Cataract

Interventions

Type	Name	Description
DRUG	Bevacizumab	Bevacizumab
DRUG	Ranibizumab	Ranibizumab
DRUG	Aflibercept	Aflibercept
DRUG	Ozurdex	Ozurdex

Timeline

• Start date: 2018-11-15
• Primary completion: 2023-09-01
• Completion: 2024-03-30
• First posted: 2019-02-06
• Last updated: 2025-09-12

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study